Syndax Pharmaceuticals EPS beats by $0.28, beats on revenue
- BySeeking Alpha-
Syndax Pharmaceuticals (SNDX) announces that the U.S
Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2 AUGMENT-101...
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule, and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer.